Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer by Tan, WS et al.
doi: 10.1111/joim.12868
Development and validation of a haematuria cancer risk
score to identify patients at risk of harbouring cancer
W. S. Tan1,2,† , A. Ahmad3,†, A. Feber1,4, H. Mostafid5, J. Cresswell6, C. D. Fankhauser7, S. Waisbrod7,
T. Hermanns7, P. Sasieni8, J. D. Kelly1,2 & DETECT I trial collaborators
From the 1Division of Surgery & Interventional Science, University College London; 2Department of Urology, University College London
Hospital; 3Cancer Intelligence, Cancer Research UK; 4UCL Cancer Institute, London; 5Department of Urology, Royal Surrey County Hospital,
Guildford; 6Department of Urology, James Cook University Hospital, Middlesbrough, UK; 7Department of Urology, University Hospital Zurich,
University of Zurich, Zurich, Switzerland; and 8Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, Innovation
Hub, Guys Cancer Centre, Guys Hospital, King’s College London, London, UK
Abstract. Tan WS, Ahmad A, Feber A, Mostafid H,
Cresswell J, Fankhauser CD, Waisbrod S,
Hermanns T, Sasieni P, Kelly JD, DETECT I trial
collaborators (University College London;
University College London Hospital; Cancer
Research UK; UCL Cancer Institute, London;
Royal Surrey County Hospital, Guildford; James
Cook University Hospital, Middlesbrough, UK;
University Hospital Zurich, University of Zurich,
Zurich, Switzerland; Guys Hospital, King’s College
London, London, UK). Development and validation
of a haematuria cancer risk score to identify
patients at risk of harbouring cancer. J Intern
Med 2019; 285: 436–445.
Background. A lack of consensus exists amongst
national guidelines regarding who should be inves-
tigated for haematuria. Type of haematuria and
age-specific thresholds are frequently used to
guide referral for the investigation of haematuria.
Objectives. To develop and externally validate the
haematuria cancer risk score (HCRS) to improve
patient selection for the investigation of haematuria.
Methods. Development cohort comprise of 3539
prospectively recruited patients recruited at 40
UK hospitals (DETECT 1; ClinicalTrials.gov:
NCT02676180) and validation cohort comprise of
656 Swiss patients. All patients were aged
>18 years and referred to hospital for the evalua-
tion of visible and nonvisible haematuria. Sensi-
tivity and specificity of the HCRS in the validation
cohort were derived from a cut-off identified from
the discovery cohort.
Results. Patient age, gender, type of haematuria and
smoking history were used to develop the HCRS.
HCRS validation achieves good discrimination
(AUC 0.835; 95% CI: 0.789–0.880) and calibration
(calibration slope = 1.215) with no significant over-
fitting (P = 0.151). The HCRS detected 11.4%
(n = 8) more cancers which would be missed by
UK National Institute for Health and Clinical
Excellence guidelines. The American Urological
Association guidelines would identify all cancers
with a specificity of 12.6% compared to 30.5%
achieved by the HCRS. All patients with upper tract
cancers would have been identified.
Conclusion. The HCRS offers good discriminatory
accuracy which is superior to existing guidelines.
The simplicity of the model would facilitate adop-
tion and improve patient and physician decision-
making.
Keywords: bladder cancer, detection, haematuria,
nomogram, predict, urinary tract cancer.
Introduction
The decision to guide who should have investiga-
tions following a presentation of haematuria varies
between guidelines [1]. Recommendations by the
National Institute for Health and Care Excellence
(NICE) suggest that patients aged ≥45 years with
visible (VH) and ≥60 years with nonvisible haema-
turia (NVH) with either dysuria or a raised white
cell count on blood test should be urgently inves-
tigated [2]. Nonurgent referral can be considered
for patients ≥60 years with recurrent or persistent
unexplained NVH [2]. In contrast, guidance from
the American Urology Association (AUA) is that all
patients with VH and patients with NVH aged
≥35 years should have diagnostic tests although†Joint first authors
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patients younger than 35 years may be referred for
cystoscopy at the discretion of the clinician [3].
Consistent across guidelines is the use of age-
specific thresholds to guide referral for the inves-
tigation of VH and NVH as increasing age is an
established risk factor for bladder cancer. Adopting
arbitrary thresholds will invariably result in an
increased likelihood of missed cancers as well as
over investigation of cases unlikely to harbour
malignancy. We have previously reported that
3.5% of patients presenting with VH and 1.0% of
patients with NVH have a diagnosis of malignancy
despite not meeting the age threshold set out in
NICE guidance [4].
Predictive and prognostic tools using statistical
models have been developed in the form of nomo-
grams enabling individual patient-specific risk
estimation [5]. Nomograms often include multiple
parameters with the advantage to outperform
specific individual variables. Whilst numerous
prognostic nomograms have been developed for
bladder cancer, there is only one risk score
reported for the prediction of a diagnosis of cancer
in patients presenting with NVH [6–8].
In this study, we report the development and
external validation of a haematuria cancer risk
score (HCRS) for the prediction of cancer to enable
both patients and physicians to easily assess
cancer risk following a presentation of haematuria.
The advantage of a risk assessment approach over
the application of arbitrary age thresholds allows a
more individualized approach with the aim to
improve detection of cancer and reduce the need
for the investigations in patients unlikely to have
malignancy.
Material and methods
Study design and population
Both the development and validation cohort com-
prise patients who were referred to secondary care
following a presentation of haematuria. NVH was
defined as urine dipstick of ≥1+ of blood on ≥2
occasions in the discovery cohort [9]. NVH was
defined by either haematuria on urine dip stick or
urine microscopy in the validation cohort due to
the absence of haematuria guidelines in Switzer-
land and the variation in physician practice pat-
terns. Patients in the development cohort were
prospectively recruited between March 2016 and
June 2017 at 40 UK hospitals whilst the external
cohort consist of patients who were retrospectively
identified as having haematuria investigations
between 2011 and 2017 from the Department of
Urology, University of Zurich. All patients were
≥18 years and were referred from primary care to
secondary care following a presentation of haema-
turia in the community. Study design and patient
eligibility criteria of the development cohort have
been previously described [10].
All patients had no previous history of a bladder
cancer diagnosis and evaluation comprised of
medical history and clinical examination. Patient
demographics, gender, ethnicity, smoking history
and occupation were recorded. Occupational risk
factor was defined as patients working as gardener,
painter, hairdresser/barber, textile worker or met-
als factory worker [11]. Cystoscopy and upper tract
imaging were performed for all patients. Where
bladder cancer was suspected, patients had a
transurethral resection of bladder tumour (TURBT)
or bladder biopsy under general anaesthesia.
Bladder cancers were defined as urothelial cell
carcinoma and other bladder cancer variants
confirmed on histology. Upper tract cancers
were also confirmed on histology and classified to
either upper tract urothelial cancer or renal cell
cancers.
The development cohort of the study received
ethical approval by Health Research Authority-
North West Liverpool Central Research Ethics
Committee on March 2016 (IRAS project ID:
179245, REC reference: 16/NW/0150). The vali-
dation cohort received ethical approval by the
Cantonal Ethics Committee of Zurich (STV KEK-
ZH BASEC-Nr. 2016-00158).
Development and validation of a novel haematuria cancer risk score
and statistical analysis
Univariate logistic regression was used to deter-
mine an association between individual variables
and bladder cancer. The outcome was bladder
cancer which was defined as Yes = 1 versus
No = 0. All cases were used for estimating odds
ratios. Age (years) was analysed as a continuous
variable whilst gender (0 = female, 1 = male), type
of haematuria (0 = NVH, 1 = VH), smoking history
(0 = nonsmoker, 1 = ex-smoker, 2 = current smo-
ker, 3 = missing) and ethnicity (0 = White,
1 = non-White, 2 = missing) as categorical vari-
ables. Multivariate logistic regression model was
performed with patient’s age, gender, type of
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haematuria and smoking were used as the final
predictors for the diagnosis of bladder cancer
(0 = No vs 1 = Yes).
A novel HCRS was developed as the linear predictor
of the fitted multivariate logistic regression in the
derivation data set and fitted as a single predictor
to the validation data set. To assess the perfor-
mance of the HCRS, the area under the curve (AUC)
was used as a measure of discrimination. The
lower and upper 95% confidence interval (CI) of the
AUC were computed as defined by DeLong et al.
[12]. The Venkatraman’s test for two unpaired
receiver operating curves (ROC) was performed
using 2000 resampling to test the null hypothesis
that the true difference in AUC is equal to 0 [13].
External validation was then performed using the
Swiss patient cohort. The prediction accuracy of
the HCRS was evaluated by the calibration slope in
the validation data set.
All statistical analyses were performed with R (R
Foundation for Statistical Computing; version
3.4.3) [14]. All applied tests were two-sided, and a
P-value < 0.05 was accepted as statistically signif-
icant. No P-value adjustment was performed for
multiple comparisons. The development cohort of
this study was registered with ClinicalTrials.gov:
NCT02676180.
Results
Patient demographics of the development and validation cohort
A total of 3539 and 656 patients were used in the
development and validation cohort, respectively.
Descriptive patient characteristics of both study
populations are shown in Table 1. Univariate
logistic regression analysis reports that older
patients (P < 0.001), patients with VH (P < 0.001),
male patients (P < 0.001), White patients
(P = 0.004) and patients with a smoking history
(P < 0.001) were significantly more likely to have a
bladder cancer diagnosis. In the development
cohort, 285 patients (8.1%) had a diagnosis of
bladder cancer and 69 patients (10.7%) had a
diagnosis of bladder cancer in the validation
cohort. Occupational risk factor was not associ-
ated with the diagnosis of bladder cancer (P = 0.8).
Distribution of patient age stratified by smoking
history and diagnosis of cancer is described using
a box plot in Figure S1. Bladder cancer
histopathological characteristics are shown in
Table S1.
Development of the haematuria cancer risk score
Spearman’s correlation between bladder cancer
predictors showed that no strong correlation was
observed between predictors (Table S2). Multivari-
ate logistic regression model reports that increas-
ing age (OR 2.9, 95% CI 2.3–3.6, P < 0.001), VH
(OR 3.9, 95% CI 2.6–5.6, P < 0.001), male gender
(OR 1.8, 95% CI 1.3–2.4, P < 0.001) and smoking
history [ex-smoker (OR 1.5, 95% CI 1.1–2.0) and
current smoker (OR 2.6, 95% CI 1.7–3.8),
P < 0.001] were independently associated with a
bladder cancer diagnosis (Table 2). Patients who
were ex-smokers were more at risk compared to
current smokers in univariate logistic regression
but following adjusting for age in a bivariate logistic
regression model and in a multivariate regression
model, current smokers were more at risk for
bladder cancer. The HCRS was developed as the
linear predictor of the fitted multivariate logistic
regression:
Haematuria cancer risk score = 0.055*Age
+ 1.348*Haematuria type + 0.576*Gender
+ 0.413*Ex-Smoker + 0.943* Current-Smoker
Validation of the haematuria cancer risk score
Figure S2 shows the distribution of the HCRS
which was similar between the two data sets.
Validation of the HCRS achieves a good discrimi-
nation with an AUC = 0.768 (95% CI 0.741–0.795)
in the development cohort and AUC = 0.835 (95%
CI 0.789–0.880) in the validation cohort (Fig. 1). No
statistically significant difference was observed
(P = 0.1015) between AUC values of the develop-
ment and validation data sets by Venkatraman’s
test with 2000 bootstraps [13]. The estimated
calibration slope in the validation data set was
1.215. The slope is greater than one, but it is not
significantly different to one (P = 0.151) hence, the
discrimination seems to be preserved.
Table 3 reports the corresponding sensitivity,
specificity, true positives and negatives and false
positives and negatives derived from the ROC curve
for selected cut-off values. A bootstrap test with
2000 replicates showed no statistically significant
difference between sensitivities of the development
and validation cohort (Table S3). Table S4 presents
the estimated age cut-off for NVH and VH patients
by smoking status for female and male patients to
identify all cancers. Figure 2 illustrates the
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probability of bladder cancer calculated from the
fitted multivariate logistic regression model for
male and female patients incorporating other risk
factors such as age, type of haematuria and
smoking history. Elderly, male smokers with VH
had the highest risk of having cancer. Figure S3
shows the haematuria cancer risk score as a
nomogram to guide who should be investigated
following haematuria.
The development cohort comprised of 55 upper
tract cancers (37 renal cell carcinoma and 18
upper tract urothelial cancer [UTUC]) whilst the
validation cohort had 12 upper tract cancers (nine
renal cell carcinoma and three UTUC). All patients
with upper tract cancers would have been selected
to have haematuria investigations using the HCRS
of >4.5.
Comparison between haematuria cancer risk score with existing
haematuria guidelines
We explored the performance of the HCRS using a
defined cut-off of 4.015, where patients with a
HCRS of ≥4.015 should have investigations follow-
ing a presentation of haematuria. This was based
on a sensitivity of approximately 97% for all
cancers. We then tested the HCRS in the Switzer-
land patient cohort. In the external validation
cohort, referral for the investigation of haematuria
based on NICE guidance would miss 12.9% (n = 9)
of all urinary tract cancers (six bladder cancers,
three renal cell cancers) reporting a sensitivity of
87.1%. Specificity for NICE guidance would equate
to 45.7% based on 268 true-negative cases and
318 false-positive cases. The AUA recommendation
for the investigation of haematuria had a sensitivity
of 100% with 80 true-negative cases and 555 false-
positive cases corresponding to a specificity of
12.6%.
By comparison, using the same HCRS threshold
(4.015), a sensitivity of 98.6% was achieved with a
corresponding specificity of 30.5% suggesting that
an additional 11.4% (n = 8) of urinary tract cancers
were detected which would have been missed if
NICE guidance were applied. The HCRSmissed one
bladder cancer, a G3 pT1 bladder sarcoma, but
reduced the number of patients requiring investi-
gations by 149 patients.
The AUA guidelines for haematuria would identify
all cancers but result in a specificity of 3.6%
compared to the 30.5% achieved by the risk
Table 1 Patient demographics of the development and validation cohorts
Variables Development cohort (n = 3539) Validation cohort (n = 656)
Age (median, IQR) [range] 68 (57, 76) [23–96]a 57 (47, 68) [18–89]b
Haematuria, n (%):
Visible 2296 (64.9) 322 (49.1)
Nonvisible 1243 (35.1) 334 (50.9)
Gender, n (%):
Male 2098 (59.3) 504 (76.8)
Female 1441 (40.7) 152 (23.2)
Ethnicity, n (%):
White 2977 (93.8)
Non-White 196 (6.2)
Smoking history, n (%):
Nonsmoker 1519 (44.6) 212 (32.3)
Ex-smoker 1387 (40.7) 154 (23.5)
Current smoker 500 (14.7) 290 (44.2)
Occupational risk factor, n (%)
Yes 529 (16.2)
No 2743 (83.8)
aAge range for discovery cohort: visible haematuria [23–96 years], nonvisible haematuria [23–90 years]. bAge range for the
validation cohort: visible haematuria [18–98 years], nonvisible haematuria [25–88 years].
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assessment approach. All patients with upper tract
cancers would have been referred for investigation.
Discussion
This study represents the development and exter-
nal validation of a HCRS to determine the risk of
urinary tract cancer in patients with VH and NVH.
We constructed the HCRS using patients from a
prospective multicentre observational study allow-
ing generalizability throughout the UK. The score
was then validated using a Swiss patient cohort
referred for the investigation of haematuria. We show
that adopting a risk score approach identified signif-
icantly more urinary tract cancers (11.4%) which
would otherwise be missed if NICE guidance was
applied and reduce the number of patients subjected
to investigations compared to AUA guidance.
This study has several strengths in its methodol-
ogy, patient cohort, ease of use and practical
applicability to real-world clinical practice. We
used a reasonable sample size of 3539 patients to
derive the HCRS. Our model had a good discrim-
inatory ability in the validation data set with an
AUC of 0.835 (95% CI 0.789–0.880) which was
higher in comparison with over 60% of prediction
risk scores developed by Memorial Sloan Kettering
Cancer Centre (MSKCC) which have an AUC of
<0.750 [15].
The prospective multicentre nature of the devel-
opment cohort allows for accurate data capture
by comparison with most risk prediction scores
which are derived from retrospective studies or
population data sets [7, 8]. External validation
using a patient cohort from a different country
confirms the risk score is robust and repro-
ducible. Finally, variables chosen represent
clinical details which are part of the standard
referral criteria for suspected cancer following a
presentation of haematuria. Hence, adopting the
HCRS would be straightforward without addi-
tional time pressures.
Loo and colleagues [16] used electronic medical
records (EMR) from Kaiser Permanente to identify
patients who had investigations for NVH to derive a
development cohort of 1973 patients and a valida-
tion cohort of 657 patients. Patients presenting
Table 2 Univariate and multivariable logistic regression models associated with bladder cancer in the development cohort.
N = 3539 (bladder cancer = 285)
Predictor Unit
Univariate Multivariable
IQR-ORa (95% CI) LR v² (d.f., P) IQR-ORa (95% CI) Dv² (d.f., P)
Age years 2.931 (2.377, 3.614) 120.07 (1, <2.2e-16) 2.892 (2.319, 3.605) 120.07 (1, <2.2e-16)
Haematuria Nonvisible 1 (ref)
Visible 4.526 (3.127, 6.551) 89.007 (1, <2.2e-16) 3.850 (2.629, 5.638) 84.119 (1, <2.2e-16)
Smokerb Nonsmoker 1 (ref)
Ex-smoker 1.917 (1.453, 2.531) 1.512 (1.132, 2.018)
Current
smoker
1.619 (1.112, 2.357) 2.568 (1.719, 3.836)
Missingb 1.223 (0.621, 2.410) 22.638 (3, 4.8e-05) 1.283 (0.636, 2.585) 24.257 (3, 2.2e-05)
Gender Female 1 (ref)
Male 2.960 (2.196, 3.990) 60.044 (1, 9.3e-15) 1.779 (1.298, 2.438) 13.812 (1, 2.0e-04)
Ethnicityc White 1 (ref)
Non-White 0.490 (0.248, 0.967) NSS
Missingb 0.496 (0.274, 0.896) 11.097 (2, 0.00389)
CI, confidence interval; IQR, interquartile range; LR, likelihood ratio; NSS, not statistically significant; OR, odds ratios;
Dv2, delta chi-square (degrees of freedom, P-value), terms added sequentially (first to last); v2, chi-square test (degrees of
freedom, P-value).
aInterquartile range odds ratios for continuous predictors and simple odds ratios for categorical predictors. Model LR v²
(d.f, P) = 242.257 (6, <2.2e-16). bFourth category for smoking ‘missing’ was created and compared to nonsmoker category
in the logistic regression analysis. cThird category for ethnicity and compared to White category in the logistic regression
analysis. Harrell’s c-index = 0.768 (95%CI: 0.741, 0.795).
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with VH were not accessed. Following multivari-
able logistic regression, they incorporated the
following variables in their Haematuria Risk Index:
history of VH <6 months, patient age ≥50 years,
smoking history, male gender and >25 RBS/HPF
on urine microscopy with a reported AUC of 0.829.
The current study which assesses both VH and
NVH patients achieves a similar diagnostic perfor-
mance using fewer variables. Limitations include
variable quality of data recorded in EMR and both
the development and validation cohorts were
derived from the same EMR [17]. History of VH
within the last 6 months was used as a variable
suggesting that these patients were evaluated for
VH rather than NVH. Further, some patients did
not have complete haematuria investigations and
were excluded introducing case selection bias. We
could not compare our risk score to that of Loo
et al. [16] due to the difference in variables
recorded.
Fig. 1 ROC curve of the haematuria cancer risk score.
AUC 0.768 (95% CI: 0.741, 0.795) in the development
cohort and AUC 0.835 (95% CI: 0.789, 0.880) in the
validation cohort. The white square, circle and triangle
give 0.972 (95% CI: 0.954, 0.989), 0.951 (95% CI: 0.923,
0.975) and 0.898 (95 %CI: 0.863, 0.930) sensitivity in the
development data set with cut-off values of 4.015, 4.386
and 4.916, respectively. Using the same cut-off values, the
black square, circle and triangle show 0.986 (95% CI:
0.957, 1.000), 0.943 (95% CI: 0.886, 0.986) and 0.857
(95% CI: 0.771, 0.929) sensitivity in the validation data
set, respectively.
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Another risk score developed by Wu and colleagues
was designed to predict the risk of developing
bladder cancer based on a case–control study of
678 patients [18]. The risk score did not have
external validation and incorporated clinical vari-
ables such as smoking history and environmental
exposure to carcinogens to achieve an AUC of 0.70
(95% CI 0.67–0.73). Incorporating mutagen sensi-
tivity data increased the AUC to 0.80 (95% 0.72–
0.82). The risk score by Wu and colleagues was
developed to identify patients at risk of developing
future bladder cancers who may benefit from
screening.
Current recommendations from NICE exclude
younger patients (<60 years with NVH and
<45 years with VH) for investigation may result in
missed cancers [4]. Age is the main discriminating
factor across guidelines and we show that the use
of the HCRS may reduce the risk of missing
cancers. In addition to age and type of haematuria,
smoking history and gender are important risk
factors for the development of bladder cancer
[1,11]. These variables are currently not used in
the decision to refer for investigations but are
collected as part of the standard assessment of
patients. We show that incorporating all four
variables in a risk assessment approach would
improve the patient selection for haematuria inves-
tigations compared to current recommendations.
The fact that 18% of patients diagnosed with
bladder cancer consult their general practitioner
≥3 times prior to referral for investigations sug-
gesting the need for less restrictive recommenda-
tions to enable prompt referral for investigations
[19].
There are several limitations in this study. The
development cohort reflects a UK haematuria
referral pattern, and although validated in a Swiss
population, further testing in non-European coun-
tries should be considered before use. As discussed
previously, recent NICE guidance recommends
referral for the investigations of patients with VH
aged ≥45 years and ≥60 for patients with NVH.
Hence, there may be case selection for patients who
were investigated although 16.9% of patients
investigated for haematuria were below these age
thresholds. Patients were recruited in secondary
care, and although guidelines for referral exist to
aid primary care decision-making, it is possible
that a case selection bias exists whereby not all
patients presenting with haematuria in primary
care are referred for investigations according to
existing guidelines. The development of a risk
assessment tool was not a preplanned analysis;
hence, we were limited by the variables we could
use. Finally, this study does not attempt to address
what are the ideal investigations which should be
used for the investigation of haematuria and we
have previously attempted to address this in pre-
vious studies [20, 21].
Fig. 2 Estimated probability of bladder cancer by age, type of haematuria and smoking history for male (a) and female (b).
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Conclusion
In this study, we report the development and
external validation of a risk assessment approach
to predict the presence of cancer in patients with
VH and NVH. The HCRS improves cancer detection
rate and performs better than existing criteria to
trigger referral for haematuria investigations. The
simplicity of the model with limited clinical vari-
ables would facilitate adoption and improve patient
and physician decision-making.
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